Literature DB >> 11277343

Efficacy and tolerability of Hairgain in individuals with hair loss: a placebo-controlled, double-blind study.

E Thom1.   

Abstract

This randomized, placebo-controlled, double-blind study was designed to investigate the efficacy and tolerability of a new agent for the treatment of hair loss, based on a marine protein, minerals and vitamins. Sixty subjects with hair loss of different aetiologies participated in the 6-month blinded phase of the study. Objective assessments indicated that the treatment was effective and subjective assessments showed a statistically significant positive effect of treatment. Exposure to the active preparation for a further 6 months in an open phase indicated a further improvement in hair growth. Exposure of the patients previously treated with placebo to the active preparation for 12 months gave similar results. Tolerability was good and no side-effects were reported. The product investigated may provide an alternative to pharmacotherapy for the treatment of hair-loss problems in individuals with androgenic alopecia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11277343     DOI: 10.1177/147323000102900101

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  5 in total

Review 1.  Interventions for female pattern hair loss.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Jan Schoones
Journal:  Cochrane Database Syst Rev       Date:  2016-05-26

2.  A Double-blind, Placebo-controlled Study Evaluating the Efficacy of an Oral Supplement in Women with Self-perceived Thinning Hair.

Authors:  Ablon Glynis
Journal:  J Clin Aesthet Dermatol       Date:  2012-11

3.  Diet and hair loss: effects of nutrient deficiency and supplement use.

Authors:  Emily L Guo; Rajani Katta
Journal:  Dermatol Pract Concept       Date:  2017-01-31

Review 4.  Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium.

Authors:  Jan Wadstein; Erling Thom; Aida Gadzhigoroeva
Journal:  Dermatol Res Pract       Date:  2020-05-05

5.  5-Bromo-3,4-dihydroxybenzaldehyde Promotes Hair Growth through Activation of Wnt/β-Catenin and Autophagy Pathways and Inhibition of TGF-β Pathways in Dermal Papilla Cells.

Authors:  Jung-Il Kang; Youn Kyung Choi; Sang-Chul Han; Hyunwoo Nam; Gilwoo Lee; Ji-Hoon Kang; Young Sang Koh; Jin Won Hyun; Eun-Sook Yoo; Hee-Kyoung Kang
Journal:  Molecules       Date:  2022-03-28       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.